Table 2.
EC50 (mean ± SEM) and maximum response (mean ± SEM) of small vessel myograph studies; # indicates P < 0.05.
| Treatment | EC50 control (mol/l) | EC50 hypoxia (mol/l) | Maximum response control (%) | Maximum response hypoxia (%) |
|---|---|---|---|---|
| ACh-CRC | 2.37∗10-7± 3.32∗10-8 | 4.75∗10-7± 6.29+10-8 # | –82.79 ± 3.78 | –75.04 ± 2.77 |
| L-NAME+ACh-CRC | 3.33∗10-7± 4.99∗10-8 | 9.54∗10-7± 2.43∗10-7 # | –62.32 ± 4.86 | –36.22 ± 5.22 # |
| Indo+ACh-CRC | 1.63∗10-7± 3.23∗10-8 | 4.00∗10-7± 6.43∗10-8 # | –87.78 ± 1.92 | –82.06 ± 2.45 |
| TRAM34+ACh-CRC | 2.02∗10-7± 6.08∗10-8 | 4.05∗10-7± 8.00∗10-8 # | –83.66 ± 1.75 | –81.43 ± 2.15 |
| UCL1684+ACh-CRC | 3.52∗10-7± 6.41∗10-8 | 2.07∗10-6± 1.36∗10-6 # | –87.54 ± 4.51 | –76.78 ± 2.77 # |
| L-NAME+Indo+SNP-CRC | 3.32∗10-8± 1.00∗10-8 | 9.37∗10-8± 2.70∗10-8 # | –89.77 ± 1.82 | –86.63 ± 2.45 |
| L-NAME+Indo+Tempol+SNP-CRC | 3.34∗10-8± 6.58∗10-9 | 6.75∗10-8± 1.53∗10-8 # | –86.53 ± 2.02 | –87.02 ± 1.81 |
| Sildenafil-CRC | 1.18∗10-6± 3.00∗10-7 | 7.14∗10-6± 2.51∗10-6 # | –89.69 ± 1.91 | –89.55 ± 1.30 |
| L-NAME+Indo+DT-2+SNP-CRC | 2.14∗10-8± 5.45∗10-9 | 4.88∗10-8± 7.91∗10-9 # | –93.37 ± 1.50 | –93.64 ± 1.78 |
| ODQ+ACh-CRC | 8.90∗10-7± 5.34∗10-7 | 1.70∗10-6± 5.68∗10-7 | –20.76 ± 6.64 | –3.03 ± 5.10 |